OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Haldorsen on the Importance of Imaging in the Diagnosis of Endometrial Cancer

January 11th 2018

Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, discusses the importance of imaging in the diagnosis of endometrial cancer.

Dr. West Discusses Chemotherapy Without Driver Mutations in NSCLC

January 11th 2018

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute at Swedish Medical Center, discusses chemotherapy in patients with non

Dr. Bauml Discusses Biomarkers in Head and Neck Cancer

January 11th 2018

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses biomarker development for patients with head and neck cancer.

Dr. Durand on Web-Based Management Technologies for Patients With Cancer

January 10th 2018

Jean-Bernard Durand, MD, Medical Director of Cardiomyopathy Services, Director of Cardiovascular Genetics Research, The University of Texas MD Anderson Cancer Center, discusses web-based management technologies for patients with cancer.

Dr. Kudchadkar on Immunotherapy in Merkel Cell Carcinoma

January 10th 2018

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses immunotherapy in Merkel cell carcinoma.

Dr. Zhang on Toxicities of Treatments in RCC

January 9th 2018

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the tolerability of agents used for the treatment of patients with renal cell carcinoma (RCC).

Dr. Domchek on Promising Biomarkers in Breast Cancer

January 9th 2018

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses promising biomarkers in breast cancer.

Dr. Graff Discusses the Treatment of Prostate Cancer

January 9th 2018

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.

Dr. Landi Discusses the Importance of Screening in Melanoma

January 9th 2018

Maria Teresa Landi, MD, PhD, senior investigator, Integrative Tumor Epidemiology Branch, National Cancer Institute, discusses the importance of screening in melanoma.

Dr. Sehouli Discusses Unmet Needs in Ovarian Cancer

January 8th 2018

Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, discusses the unmet needs for patients with ovarian cancer.

Dr. O'Reilly on Immunotherapy in Pancreatic Cancer

January 8th 2018

Eileen O'Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy in patients with pancreatic cancer.

Dr. Ruan on Lenalidomide Plus Rituximab in MCL

January 8th 2018

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell, NewYork-Presbyterian Hospital, discusses the combination of lenalidomide (Revlimid) plus rituximab (Rituxan) in mantle cell lymphoma.

Dr. Gasparetto on Next Steps With Selinexor and Daratumumab in Multiple Myeloma

January 8th 2018

Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses the next steps with selinexor and daratumumab (Darzalex) in multiple myeloma.

Dr. Martin on Trial of Oral Azacitidine Plus R-CHOP in High Risk DLBCL

January 6th 2018

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses a trial of the combination of oral azacitidine (CC-486) and R-CHOP in diffuse large B-cell lymphoma (DLBCL).

Dr. Flinn on Next Steps With Venetoclax Plus Obinutuzumab in CLL

January 6th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses next steps with venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).

Dr. Paik Discusses Advances in Squamous Cell Lung Cancer

January 6th 2018

Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses recent advancements in squamous cell lung cancer.

Dr. Oh on the Hormone-Sensitive Setting in Prostate Cancer

January 6th 2018

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the hormone-sensitive setting of prostate cancer.

Dr. Yardley Discusses Enzalutamide in HR+ Breast Cancer

January 6th 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the randomized placebo-controlled phase II trial evaluating exemestane with/without enzalutamide (Xtandi) in patients with hormone receptor (HR)-positive breast cancer

Dr. Galsky on Progression on Immunotherapy in Bladder Cancer

January 6th 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses the next steps following progression on immunotherapy for patients with bladder cancer.

Dr. Martin on FDA Approval of Denosumab in Multiple Myeloma

January 5th 2018

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses the FDA approval of denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.